Objectives This article evaluated the drug loading, release kinetics, and matrix metalloproteinase (MMP) inhibition of doxycycline (DOX) released from DOX-loaded nanotubemodified adhesives. DOX was chosen as the model drug, since it is the only MMP inhibitor approved by the U.S. Food and Drug Administration. Materials and methods Drug loading into the nanotubes was accomplished using DOX solution at distinct concentrations. Increased concentrations of DOX significantly improved the amount of loaded DOX. The modified adhesives were fabricated by incorporating DOX-loaded nanotubes into the adhesive resin of a commercial product. The degree of conversion (DC), Knoop microhardness, DOX release kinetics, antimicrobial, cytocompatibility, and anti-MMP activity of the modified adhesives were investigated.
Introduction
Over the past decade, resin composites have become the material of choice for direct restoration of teeth compromised by dental caries due to their esthetic properties and minimally invasive cavity preparations [1] . However, resin composite restorations have an average lifetime of only 5.7 years [2] . Secondary caries that develops at the interface between resin composite restoration and dental tissue (dentin/enamel) is the primary reason for restoration replacement [3] .
Although the field of adhesive dentistry has greatly evolved over the years, the basic principles of bonding to tooth structure remain unchanged. It is critical to achieve a micromechanical interlocking (adhesive resin/tooth structure) to obtain a stable and durable bond [4] . This process has been termed Bhybridization^or the formation of the hybrid layer [5] . The hybrid layer (HL) is the zone where resin monomers flow and polymerize into acid-etched dentin to establish micromechanical interlocking with the demineralized collagen matrix. Unfortunately, suboptimal resin monomer infiltration leaves behind a denuded collagen matrix susceptible to endogenous protease activity (i.e., matrix metalloproteinases (MMPs) and cathepsins) that will digest the unprotected collagen and deteriorate the HL over time [2, 6] and may contribute to the secondary caries formation.
In recent years, several strategies including the use of MMP inhibitors [7, 8] and chelating agents (e.g., chlorhexidine) [9, 10] have been suggested to counteract and/or inhibit the activity of MMPs and cathepsins. Yet, the levels of MMPs and/or cathepsin inhibition and associated bond stability were not sustained after long-term (> 18 months) aging [10, 11] . Taken together, these findings strongly highlight the pressing need to discover a clinically translatable strategy that would support a localized and sustained release of MMP and/or cathepsin inhibitors.
Aluminosilicate (Halloysite®, Halloysite nanotube [HNT] ) is a naturally occurring tubular clay formed by rolled kaolin with a general length between 500 and 1500 nm [12] . Interestingly, the inner surface of HNT has chemical properties similar to those of Al 2 O 3 as it is formed by the octahedral sheet of Al-OH, while the outer surface has chemical properties identical to those of SiO 2 resulting from siloxane groups (Si-O-Si) [12] . This difference in chemical composition results in a negatively charged outer surface and a positively charged inner lumen approximately 10-15 nm in diameter [12] . With this as the goal, our group recently started to report on a novel strategy of modifying dental adhesives with these clay nanotubes [13] [14] [15] [16] to deliver MMP inhibitors (e.g., doxycycline [DOX] ) at the HL level to enhance resin-dentin bond durability. Our seminal proof-of-concept data clearly demonstrated the inhibition of MMP-1 activity by eluates obtained from DOX-loaded nanotube-modified adhesives when testing the effects of a 10% (w/v) doxycycline solution [14] . Our previous work lacks detailed information on the release kinetics and concentration range of loaded DOX, since the MMP inhibition by the DOX eluate was 13.4%. The aim of this study was to further evaluate the loading potential and MMP-inhibiting effects of different concentrations of DOX-loaded nanotube-modified dental adhesives by including thorough high performance liquid chromatography ([HPLC]/mass spectroscopy) analyses to appreciate the drug-loading potential and release kinetics. We hypothesized that increased concentrations of DOX would not compromise the physicochemical properties of the modified adhesive and would show higher release of DOX and MMP inhibition without toxicity.
Materials and methods

Preparation of doxycycline solutions and nanotube loading
Doxycycline hyclate (DOX, Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 5 mL of 50 mM HEPES buffer (pH7.2, Fisher Scientific, Pittsburgh, PA, USA) at three distinct concentrations (w/v): 10% (0.5 g), 20% (1 g), and 30% (1.5 g) by stirring (Fisher Thermix, model 310 T, Fisher Scientific). The loading process started by mixing a predetermined amount (1.25 g) of pre-sieved (< 45 μm) Halloysite® nanotubes (HNT, Dragonite 1415JM, Applied Minerals Inc., New York, NY, USA) in 5 mL of each DOX solution and followed by sonication for 2 h [19] . In order to minimize any air between and within the nanotubes, the solutions were placed in a vacuum (25 in. Hg) chamber for 1 h. Next, the solutions were mixed for 1 h and vacuum was reapplied [14] . Finally, the HNT + DOX solutions were centrifuged (3000 rpm) for 10 min. The supernatants were collected and stored at − 20°C for high-pressure liquid chromatography (HPLC) analysis. Meanwhile, the HNT + DOX pellets were dried at 37°C, weighed, ground, and sieved.
Loading efficiency and drug loading
The amount of DOX in the supernatants (SUPs) after the loading process was assayed by HPLC (1100 Series, Agilent Technologies, Palo Alto, CA, USA) equipped with a UV-Vis detector. An Eclipse XDB-C18 (Agilent Technologies) chromatography column (3.5 μm, 150 × 4.6 mm) and 10 μL injection volume were used. A binary mobile phase consisting of solvent systems A and B was used in an isocratic elution with 80:20 A:B. Mobile phase A was 50 mM of KHPO 4 in dH 2 0 and mobile phase B was 100% acetonitrile. The HPLC flow rate was 1.0 mL/ min and the total run time was 10 min. The retention time was 4.85 min. The concentration of DOX was calculated based on a standard curve of known levels of DOX at 273 nm. The amount of unloaded and loaded DOX was calculated as follows:
Loading efficiency and drug loading were obtained using the eqs. [17] :
Where: D a = total DOX added (g), D s = unloaded DOX (g), and N a = total HNT (1.25 g).
Doxycycline-loaded nanotube-modified dental adhesive fabrication
The experimental adhesives were prepared by mixing using a stirrer and conical micropestle [13] [14] [15] [16] . DOX-loaded (10, 20, and 30% DOX) nanotubes were added to a commercially available adhesive (Adper Scotchbond Multi-Purpose [SBMP], 3M ESPE, St. Paul, MN, USA) at 15% (w/v, 75 mg of HNT + DOX in 500 μL of adhesive) and sonicated to enhance HNT dispersion [13] [14] [15] [16] . Foil-covered light-proof (amber) microcentrifuge tubes were used during the fabrication process due to DOX photosensitivity [18] . Control groups consisting of unmodified adhesive (SBMP) and DOX-free nanotube-modified adhesives were also fabricated. All specimens were prepared in a constant-temperature room (23°C) equipped with a filtered lighting system to lessen inadvertent polymerization.
Degree of conversion (DC)
Adhesive disks (7 × 0.24 mm, n = 5/group) were fabricated with a Teflon® mold by adhesive resin light curing using a light-emitting diode curing unit (Demi LED, Kerr, Orange, CA, USA). 
Knoop microhardness
Five disk-shaped (6.2 × 1.0 mm, n = 5/group) adhesive specimens were prepared by light curing (20 s/side) for Knoop microhardness analyses. The specimens were then mounted in self-cure epoxy resin (EpoxiCure®, Buehler, Lake Bluff, IL, USA) and finished with 1200-grit SiC paper (Buehler). The specimens were subjected to a microhardness test (M-400, LECO Corporation, St. Joseph, MI, USA) using a Knoop diamond indenter at a 50-gf load and 15-s dwell time [13] . Five readings at different locations were taken from each specimen. The long diagonal length was measured immediately and converted to a KHN number (kg/mm 2 ). The adhesive specimens used for the assays described below were fabricated following this protocol.
Drug release profile from DOX-loaded nanotube-modified dental adhesives Disk-shaped specimens (n = 6/group) were fabricated and individually incubated at 37°C in 1 mL of phosphate buffer saline ([PBS] pH7.4, Fisher Scientific). Then, 150 μL of aliquots (PBS eluates) were collected after 1, 7, 14, 21, and 28 days. An equal volume of fresh PBS was added back to keep the volume constant. Aliquots were stored at − 20°C until used for high performance liquid chromatography tandem mass spectrometry (HPLC-MS-MS, Agilent 6460 Triple Quadrupole LC/MS, San Jose, CA, USA). The analysis was performed using an XBridge C18 chromatography column (3.5 μm, 100 × 2.1 mm) with a 5-μL injection volume. The mobile phase consisted of 0.1% formic acid in deionized water (A) and 0.1% formic acid in acetonitrile (B) under an isocratic condition (A:B, 80 :20) . A flow rate of 0.30 mL/min was used. The mass spectrometer was operated in multireaction monitoring (MRM) mode. The transition for doxycycline was mass:charge (m/z) at 445.1 (MS1) and 428.1 (MS2). The concentration of released DOX was calculated based on a standard curve prepared for DOX solution at known concentrations (r 2 = 0.99986).
DOX content in the nanotube-modified dental adhesive and after long-term storage
The total DOX content in the freshly prepared adhesive disks (n = 4/group) and after 4 months of storage in PBS at 37°C was determined by dissolving the specimens in dimethyl sulfoxide ([DMSO] Fisher Scientific). Next, the solubilized DOX-containing adhesive/DMSO solutions were centrifuged (4000 rpm) and the supernatants were collected and stored at − 20°C until analyzed by mass spectrometry. The overall outcomes were to determine (1) the total amount of DOX that was incorporated into the adhesive specimens and (2) the amount of DOX remaining in each specimen after 4 months.
Antimicrobial properties of DOX-loaded nanotube-modified dental adhesives
Disk-shaped specimens (n = 3/group) were fabricated and disinfected by ultraviolet (UV) irradiation (30 min/side) for antimicrobial analyses [14] . Streptococcus mutans (S. mutans, UA159) and Lactobacilli casei (L. casei, ATCC 393) were cultured aerobically in tryptic soy broth (Difco Laboratories, Detroit, MI, USA) for 24 h in 5% CO 2 at 37°C. Then, 100 μL of the bacterial suspension was swabbed onto blood agar plates to individually create lawns of the selected bacteria [14, 19] . The agar plates were divided into zones and adhesive disks or 10 μL of previously collected eluates was placed onto the plates (bioMérieux, Inc., Durham, NC, USA) [14] . The blood agar plates were incubated in 5% CO 2 at 37°C. After 72 h, the inhibition zones (mm) were measured. Chlorhexidine (0.12%) and sterile PBS were used as the positive and negative controls, respectively.
Cytocompatibility
UV-disinfected, disk-shaped specimens (n = 4/group) were used to prepare eluates from the adhesives, according to the guidelines of the International Standards Organization (1993) [20] . The specimens were individually soaked in 15 mL of low glucose Dulbecco's Modified Eagle's Medium ([DMEM] Gibco, Grand Island, NY, USA) supplemented with 10% FBS (HyClone, Logan, UT, USA) and 1% penicillin-streptomycin (Sigma-Aldrich). The eluate extraction was performed at 37°C (24 h) under agitation. Next, the eluates were serially diluted to 32-, 64-, and 128-fold [21] . Human dental pulp stem cells ([hDPSCs] AllCells LLC, Alameda, CA, USA) were cultured under standard conditions in a humidifier incubator (5% CO 2 /95% air) at 37°C in low-glucose DMEM supplemented with 10% FBS (HyClone) and 1% penicillin-streptomycin (Sigma). Cytotoxicity was performed as previously described [14] using WST-1 assay (Roche Diagnostics, Indianapolis, IN, USA) according to the manufacturer's instructions. Cell viability data (%, mean ± SD) are presented as determined from the ratio of experimental value to value from untreated cells.
Anti-MMP activity of DOX-loaded nanotube-modified dental adhesives
The anti-MMP activity of DOX-loaded nanotube-modified adhesives was determined by testing eluates collected in Trishydroxymethylaminomethane (Tris) buffer over 28 days using a fluorescein isothiocyanate (FITC)-labeled type I collagen cleavage assay.
Eluate preparation from DOX-loaded nanotube-modified dental adhesives
Disk-shaped specimens (n = 4/group) were fabricated as previously described and used to prepare eluates from the experimental adhesives and controls (i.e., SBMP and DOX-free nanotube-modified adhesive). The specimens were individually incubated at 37°C in 1 mL of Tris buffer (pH7. 
FITC-labeled type I collagen cleavage assay
Type I collagen derived from rat-tail tendon (RTT) was purified and labeled with fluorescein isothiocyanate (FITC, Sigma-Aldrich) [22] . Human pro-matrix metalloproteinase 1 (pro-MMP-1, 0.05 mg/mL, Abcam, C a m b r i d g e , M A , U S A ) w a s a c t i v a t e d w i t h 4 -aminophenylmercuric acetate ([APMA] Sigma-Aldrich) [23] . Successful activation was confirmed using Western blot analysis [24] . All the eluates (150 μL, n = 4/group) collected from the fabricated adhesives in Tris buffer were incubated with APMA-activated MMP-1 for 30 min at RT. Then, Tris buffer (200 μL) and FITC-labeled type I collagen (50 μL) were added and the mixture was incubated at 37°C for 120 min. The negative and positive controls for the assay were Tris buffer and a 0.1% DOX solution, respectively. Samples (70 μL) were periodically (0-120 min) removed and the reaction was terminated by the addition of 1,10-phenanthroline (200 mM, 10 μL) to a final concentration of 25 mM [28] . Reducing SDS-PAGE sample buffer was added (1:1); samples boiled for 10 min, and then resolved in 8% SDS-PAGE (150 V, 3 h). The fluorescent signals were captured using the Bio-Rad imaging system (Gel Doc™ XR imaging system). The fluorescence intensity at 0 min and 120 min incubation was analyzed with ImageJ software (National Institutes of Health, Bethesda, MD, USA). The percent of FITC-labeled RTT of buffer, 0.1% DOX (positive control), and the eluate collected from the adhesives was calculated as follows [22] :
The percent (%) of MMP inhibition was calculated using the following equation:
Transmission electron microscopy (TEM)
TEM analysis was carried out on resin composite/HNTmodified experimental adhesive samples in order to confirm the presence of the nanotubes (HNTs) within the adhesive resin.
Resin composite/SBMP specimens were also prepared for comparison purposes. Disk-shaped specimens (7 × 2 mm) were fabricated using a custom-made silicone mold (Exaflex Putty, GC America Inc., Alsip, IL, USA). Next, resin composite ([RC] Durafill VS shade A2, Heraeus Kulzer GmbH, Dirmagen, Germany) was placed into the mold and cured for 40 s, followed by application of the nanotube-modified adhesive (DOX-free) and light curing for 20 s. Likewise, the control specimens were prepared using the SBMP adhesive resin. The specimens were cut to produce approximately 2 × 2 × 2 mm 2 beams using a diamond disk before TEM preparation [25] . Ultrathin sections (70-90 nm) were taken from the resin blocks containing the RC/adhesive samples using a diamond knife (Diatome, Electron Microscopy Sciences, Hatfield, PA, USA), placed on copper mesh grids and then imaged at 80 kV (TEM, Tecnai BioTWIN, FEI, Hillsboro, OR, USA).
Statistical analysis
The data were analyzed using one-way analysis of variance (ANOVA) followed by Tukey's test for multiple comparisons. A significance level was set at α = 0.05.
Results
Loading efficiency and drug loading
Statistical analyses revealed significant (p < 0.001) differences in the amount of loaded DOX, loading efficiency, and drug loading among the three groups (Table 1) . Overall, increases in the concentration of DOX significantly increased the amount of DOX that was loaded into the HNTs. Meanwhile, increases in the concentration of DOX significantly decreased loading efficiency.
Degree of conversion (DC)
DC data for the control (SBMP) and modified adhesives polymerized for 10, 20, or 40 s are shown in Fig. 1 
Knoop microhardness
The Knoop microhardness values for the adhesives tested are shown in Fig. 2 . There were no significant (p > 0.05) differences between the nanotube-modified dental adhesives (with or without DOX) when compared to the control (SBMP).
Drug release profile from DOX-loaded nanotube-modified dental adhesives
An initial burst release was seen at day 1 and followed by a gradual decrease over time (Fig. 3) . The cumulative release of DOX (mean ± SE) from the adhesive over 28 days was 4.04 ± 0.05 μg (10% DOX), 4.79 ± 0.07 μg (20% DOX), and 8.21 ± 0.088 μg (30% DOX). No significant differences in the DOX cumulative release were found among the groups (p = 0.259).
DOX content in the nanotube-modified dental adhesive and after long-term storage
When specimen disks were dissolved in DMSO, the total DOX content in the adhesive disks ranged from 292.51-1644.17 μg (10-30%DOX). After long-term storage (4 months), the amount of DOX in the adhesive disks decreased to as low as 39.77 μg (10% DOX). The percent (%) remaining in the adhesive disks was 13.60 (10% DOX), 6 .09 (20% DOX), and 6.24 (30% DOX), when compared to the original amount of DOX present in the dental adhesives.
Antimicrobial properties
Representative photographs shown in Fig. 4 demonstrate significant growth inhibition of S. mutans and L. casei. The inhibition zones for both bacteria when in contact with the DOX-loaded nanotube-modified adhesives were seen as a function of the amount of DOX within the adhesives. Statistical analysis showed that inhibition zones for S. mutans and L. casei were significant among the three groups, except for the inhibition zone of L. casei, which was between 10% DOX and 20% DOX.
Cytocompatibility Figure 5 shows hDPSC viability (%) following exposure to eluates collected from the experimental adhesives and the control. No significant differences (p > 0.05) were found among cells incubated with eluates, at the same dilution, for each adhesive when compared with the control group (i.e., cells that were not incubated with eluate, 100% survival).
Anti-MMP activity of DOX-containing eluates FITC-labeled type I collagen cleavage assay demonstrated significant MMP-1 inhibition by DOX-containing eluates (Fig. 6) 
Transmission electron microscopy (TEM)
Representative scanning and transmission electron micrographs of the clay nanotubes showed the unique hollow structure approximately 50-100 nm in width and an estimated length in the range of 200-1000 nm ( Fig. 7a and b) . TEM micrographs of the interface between RC and the nanotubemodified adhesive are shown in Fig. 7c and d . Note the presence of small clusters of nanotubes (white arrows).
Discussion
Over the past decade, the body of work discussing new material-and clinical-based strategies to prolong the durability and overall clinical success of composite restorations through the use of molecules or compounds capable of inhibiting the activity of endogenous proteases has grown exponentially [7] [8] [9] [10] [11] 26] . This study provides in-depth details on the loading potential of doxycycline (DOX) onto aluminosilicate nanotubes and its MMP-1 inhibition effects over time upon its release. The results of DOX loading determined by HPLC showed that increased concentrations of DOX significantly amplified the amount of loaded DOX (Table 1) . Conversely, higher concentrations of DOX significantly decreased loading efficiency, possibly due to a threshold limit, since the amount of HNT used for loading was constant, regardless of the DOX concentration used. A study conducted by Qi et al. reported a similar trend when HNT was loaded with tetracycline [27] .
Since HNT is positively charged on the inner surface and negatively charged on the outer surface, the driving force for drug loading relies on the differences in charge between the cationic DOX [28] and the negatively charged HNT outer surface. Results from Table 1 indicate that part of DOX is absorbed outside of the lumen which is approximately 10% by volume of the tubes and additional loaded DOX may occur in the Bpockets^formed between each layer of these multilayer aluminosilicate clay nanotubes due to loose attachment [29] . Moreover, when vacuum is applied, DOX may be pushed into the lumen of HNT due to negative pressure, regardless of the charge of the materials. In terms of physicochemical properties, the modification of the adhesive resin with DOX-loaded nanotubes did not compromise DC (compared within the same curing time, Fig. 1 ) and microhardness ( Fig. 2 ) compared to the control (p > 0.05). These results suggested that even though DOX incorporation led to a darker adhesive, it did not jeopardize monomer conversion and also the release of DOX was not due to underpolymerized adhesive. Microhardness was performed since it indirectly measures DC on specimens with the same dimensions as those used in the drug release studies to ensure that polymerization of modified adhesives was not affected by specimen thickness. A strong correlation (r 2 > 0.9) has been shown to exist between DC and microhardness [30] .
The drug release profile showed an initial burst release at day 1, followed by a gradual decrease over time (Fig. 3) . Even though the release of DOX revealed an initial burst that may not be sustained for long term, clinically, DOX released from the modified adhesive would be localized at the hybrid layer where the active MMPs are present. Interestingly, although a higher concentration of DOX (> 30%, w/v) could provide the greatest release, the concentration used in this study was limited by solubility and the pH of DOX. Indeed, DOX was not completely dissolved at concentrations higher than 30% (w/v). Moreover, the increased concentration of DOX significantly decreased the pH of the DOX solution (30% DOX pH~3.5 and 50% DOX pH~1). Taking into consideration that the pH of the adhesive resin of SBMP is approximately 3.5-4.0, the increased concentration of DOX could lead to a significant pH drop upon the adhesive's modification, which, in turn, could alter the overall properties of the adhesive or the adhesive/ demineralized dentin interactions.
The cumulative release over 28 days was approximately 1-2% of the amount of DOX initially incorporated within the adhesive disks, demonstrating, for the first time, the great reported to be approximately 24 h in vivo or in cell culture conditions [31, 32] . Therefore, it would be beneficial to investigate the effects of other MMP inhibitors such as epigallocatechin gallate or tissue inhibitor of MMPs.
The antimicrobial properties obtained through agar diffusion tests revealed inhibition zones for S. mutans and L. casei when in contact with the DOX-loaded nanotube-modified adhesives were seen as a function of the amount of DOX within the adhesives (Fig. 4) . This indicates that DOX was successfully incorporated into the modified adhesive and remained active even after it was processed through the loading testing method used in this study. Most importantly, the eluates prepared from DOX-loaded nanotube-modified adhesives did not inhibit growth of either bacterial strain tested, thus indicating that the concentration of DOX released from the specimens was below MIC for S. mutans (0.25-0.50 mg/mL) and L. casei (0.38-1.5 mg/mL) [33] . Furthermore, the eluates for all adhesives tested were considered not toxic to hDPSCs (p > 0.05, Fig. 5 ) when compared with the control group (i.e., cells that were not incubated with eluate, 100% survival).
Anti-MMP properties of the experimental DOX-loaded nanotube-modified adhesives were determined based on a FITC-labeled type I collagen assay as the substrate for MMP-1 using the eluates obtained from the adhesives over 28 days. MMP-1 was used since only MMP-1, MMP-8, and MMP-13 are true collagenases and thus cleave fibrillar collagen more efficiently than other MMPs. Furthermore, MMP-1 has also been found in dentin, along with MMP-2, MMP-3, MMP-8, and MMP-9 [34] [35] [36] . Overall, DOX-containing eluates from day 1 showed the highest MMP inhibition (16.20-26 .33%) and progressively decreased over 28 days (Fig. 6) . No significant differences in the released DOX among 10, 20, and 30% DOX were found at any time point. The degree of MMP-1 inhibition by DOX-containing eluates gradually decreased over time compared to the negative control (Tris buffer). No significant differences in MMP-1 inhibition were found among the 10, 20, and 30 DOX groups (p > 0.05).
The DOX mechanism of inhibition occurs through the chelation of zinc present in the catalytic domain of the MMPs. In this study, native/helical type I collagen derived from rat-tail tendons was used. Worth mentioning, this assay may not provide the true degradation in dentin, because the demineralized dentin may be composed of both denatured and native type I collagen. Moreover, the accessibility of released DOX to bind with MMPs needs to be further investigated. Nevertheless, Toledano et al. (2012) demonstrated that DOX may completely block dentin MMPs for at least 4 weeks [37] . MMPs contain a zinc ion in the catalytic domain and a non-exchangeable zinc ion that helps to stabilize the MMP structure. Moreover, MMPs also contain two or three calcium ions. The MMP inhibition of DOX may also occur through the binding of enzyme-associated calcium, thus changing their conformation and eventually resulting in inactivation of the MMPs. This may explain the long lasting and potent inhibition produced by DOX rather than by the sole interaction with the catalytic zinc [38] . Furthermore, DOX may not be suitable for bonded dentin interfaces because MMPs are known to participate in dentin mineralization and it has been previously reported that DOX will inhibit other tissue repair processes [39] . However, what remains is to determine whether this nonselective inhibition of enzymes by zinc/calcium chelators can adversely interfere with the calcification of reparative dentin.
Representative scanning and transmission electron micrographs of the nanotubes are shown in Fig. 7a and b , respectively. TEM micrographs of the interface between a resin composite and the nanotube-modified adhesive clearly showed the presence of small clusters of nanotubes ( Fig. 7c and d) that was not observed in the control (Fig. 7e and f) , further supporting the hypothesis that nanotubes can be dispersed within the adhesive resin-based matrix and serve as a nanocontainer for drug release, even though this study lacks information regarding immediate and long-term resin-dentin bond durability.
Conclusions
The current study details the loading potential and MMP inhibition of DOX released from the modified adhesive. Higher DOX led to higher drug loading into HNT and MMP inhibition in a concentration-dependent manner without altering the physicochemical properties of the adhesives and cytotoxicity.
